decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2001 / B-01-49
Subscribe or sign in to view the full article.
Article Overview
This CMS Program Memorandum provides clarification for Medicare carriers on how to handle influenza vaccine pricing updates under existing drug and biological payment methodology. It is relevant to Medicare billing and reimbursement staff who track seasonal vaccine payment allowances, CMS guidance, and FDA-related product availability updates.
Why This Topic Matters
The memo explains a seasonal Medicare payment update process that affects how carriers review and publish flu vaccine payment allowances. It helps billing and reimbursement teams understand which CMS guidance applies during the annual update cycle.
Article Sections
-
Program Memorandum Header and Transmittal Information
Identifies the issuing federal agencies, transmittal information, date, and change request reference for the memorandum.
-
Subject and Payment Allowance Clarification
Summarizes the Medicare payment allowance topic and explains that the memo clarifies how existing pricing methodology should be applied for seasonal influenza vaccine products.
-
Implementation and Retention Guidance
Addresses administrative follow-up for carriers, including publication of updated allowance information and the memorandum’s temporary retention period.
What You Will Learn
- The purpose of a CMS Program Memorandum related to influenza vaccine reimbursement
- How the memorandum fits within existing Medicare drug and biological pricing guidance
- What administrative actions carriers are instructed to take after receiving the update
- How FDA-related product availability is tied to the seasonal payment allowance process
Who Should Read This
- Medicare carriers
- Medical billers and coders
- Reimbursement specialists
- Healthcare compliance staff
- Practice managers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com